Back to search

Article

Comparison of Momelotinib, Pacitinib and Ruxolitinib in patients with Myeloproliferative Neoplasm: An Indirect-Comparison Meta-Analysis of Randomized Controlled Trials

2020-06-02

Abstract excerpt

<title>Abstract</title> <p>Background The meta-analysis compared the efficacy and safety of momelotinib, ruxolitinib and pacitinib in patients with myeloproliferative neoplasms(MPN), which includes essential thrombocythemia, polycythemia vera and primary myelofibrosis. Methods We searched multiple databases and collected relevant studies before Dec. 20,2019. According to predefined criteria, we included eight q...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
2310800a-3a91-5e3e-ac7a-04984928d390
DOI
10.21203/rs.3.rs-29345/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Comparison of Momelotinib, Pacitinib and Ruxolitinib in patients with Myeloproliferative Neoplasm: An Indirect-Comparison Meta-Analysis of Randomized Controlled TrialsDOI 10.21203/rs.3.rs-29345/v1
Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.Semantic proximity
A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis.Semantic proximity
A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence.Semantic proximity
Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations.Semantic proximity
Efficacy and safety of anti-VEGF/VEGFR monotherapy and combination with immune checkpoint inhibitors for advanced or metastatic renal cell carcinoma: A network meta-analysisSemantic proximity
Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial.Semantic proximity
Molnupiravir Compared to Nirmatrelvir/Ritonavir for COVID-19 in High-Risk Patients with Haematological Malignancy in Europe. A Matched-Paired Analysis from the Epicovideha RegistrySemantic proximity
Outcomes of patients with myelofibrosis treated with compassionate use pacritinib: a sponsor-independent international study.Semantic proximity
Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial.Semantic proximity
Clinical efficacy and safety of ruxolitinib in the management of myelofibrosis: A single institution experience in Taiwan.Semantic proximity
Matching-adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myelomaSemantic proximity
Pacritinib demonstrates spleen volume reduction in patients with myelofibrosis independent of JAK2V617F allele burden.Semantic proximity
Select a neighboring publication to make it the new centre.